Gastric Cancer

Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies to improve survival rates in patients presenting with both localized and advanced disease. The recent approval of Herceptin (trastuzumab; Roche/Chugai) may pave the way for the introduction of more novel drugs.

Scope

• Analysis of the gastric cancer market based on a survey of 180 oncologists and GI specialists, supported by interviews with key opinion leaders.
• Epidemiologic forecasts of the gastric cancer patient populations in the seven major pharmaceutical markets.
• In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for gastric cancer patients.
• Discussion of unmet needs and overview of late-stage pipeline drugs.

Contains 204 pages